Product Name:Ethyl 3-ethoxy-2-propenoate

IUPAC Name:ethyl (2E)-3-ethoxyprop-2-enoate

CAS:1001-26-9
Molecular Formula:C7H12O3
Purity:98%
Catalog Number:CM247241
Molecular Weight:144.17

Packing Unit Available Stock Price($) Quantity
CM247241-250g in stock œǠ
CM247241-500g in stock ŭȋǺ
CM247241-1000g in stock ƅƻƅ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:1001-26-9
Molecular Formula:C7H12O3
Melting Point:-
Smiles Code:O=C(OCC)/C=C/OCC
Density:
Catalog Number:CM247241
Molecular Weight:144.17
Boiling Point:195.5°C at 760 mmHg
MDL No:MFCD00009863
Storage:Store at 2-8°C.

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Repotrectinib
Repotrectinib receives approval for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) from the U.S. FDA on November 15, 2023. ROS1 gene is altered in about 1-2% of patients with NSCLC. ROS1-positive lung cancer tends to be aggressive and can spread to the brain and the bones.
Repotrectinib is a highly potent and differentiated small molecule TKI that binds inside the ATP pocket, and is active against both wild-type and resistant mutations, including solvent front and gatekeeper mutations. Repotrectinib is expected to enter the U.S. market in mid-December 2023.